Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lipoproteins | 24 | 2024 | 882 | 4.760 |
Why?
|
Cardiovascular Diseases | 91 | 2024 | 15757 | 4.650 |
Why?
|
Cholesterol, HDL | 32 | 2023 | 1817 | 3.950 |
Why?
|
Cholesterol, LDL | 44 | 2024 | 2420 | 3.930 |
Why?
|
Lipoproteins, LDL | 16 | 2020 | 641 | 3.540 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 34 | 2024 | 3334 | 3.440 |
Why?
|
Fasting | 19 | 2021 | 1603 | 3.300 |
Why?
|
Lipoprotein(a) | 16 | 2024 | 499 | 3.210 |
Why?
|
Triglycerides | 33 | 2022 | 2476 | 2.910 |
Why?
|
Fluorobenzenes | 9 | 2014 | 180 | 2.670 |
Why?
|
Primary Prevention | 16 | 2024 | 1207 | 2.510 |
Why?
|
Atherosclerosis | 27 | 2023 | 3517 | 2.160 |
Why?
|
Lipids | 16 | 2024 | 3336 | 2.070 |
Why?
|
Dyslipidemias | 10 | 2024 | 895 | 2.040 |
Why?
|
Amino Acids, Branched-Chain | 9 | 2022 | 264 | 2.020 |
Why?
|
Fatty Acids, Omega-3 | 19 | 2024 | 1387 | 1.920 |
Why?
|
Coronary Disease | 15 | 2024 | 5990 | 1.890 |
Why?
|
Aspirin | 13 | 2022 | 3364 | 1.790 |
Why?
|
Lipoproteins, HDL | 10 | 2024 | 667 | 1.750 |
Why?
|
Polysaccharides | 9 | 2024 | 1016 | 1.680 |
Why?
|
Diet, Mediterranean | 5 | 2024 | 735 | 1.650 |
Why?
|
Women's Health | 15 | 2021 | 2056 | 1.650 |
Why?
|
Sulfonamides | 10 | 2017 | 1977 | 1.540 |
Why?
|
Inflammation | 20 | 2024 | 10756 | 1.360 |
Why?
|
Hypertriglyceridemia | 6 | 2021 | 316 | 1.360 |
Why?
|
C-Reactive Protein | 16 | 2022 | 3839 | 1.320 |
Why?
|
Postprandial Period | 9 | 2020 | 315 | 1.290 |
Why?
|
Pyrimidines | 9 | 2014 | 3016 | 1.290 |
Why?
|
Apolipoprotein A-I | 7 | 2020 | 297 | 1.260 |
Why?
|
Lipoproteins, VLDL | 7 | 2020 | 201 | 1.110 |
Why?
|
Exercise | 9 | 2022 | 5787 | 1.100 |
Why?
|
Risk Factors | 89 | 2024 | 74359 | 1.080 |
Why?
|
Platelet Aggregation Inhibitors | 10 | 2022 | 3201 | 1.070 |
Why?
|
Acute-Phase Proteins | 6 | 2023 | 250 | 1.050 |
Why?
|
Risk Assessment | 37 | 2024 | 24123 | 1.050 |
Why?
|
Acetylglucosamine | 4 | 2023 | 189 | 1.040 |
Why?
|
Cholesterol | 12 | 2023 | 2924 | 1.040 |
Why?
|
Apolipoproteins B | 7 | 2023 | 388 | 0.970 |
Why?
|
Diabetes Mellitus, Type 2 | 20 | 2023 | 12293 | 0.970 |
Why?
|
Exercise Test | 6 | 2021 | 2128 | 0.950 |
Why?
|
Magnetic Resonance Spectroscopy | 13 | 2024 | 3765 | 0.950 |
Why?
|
Cholecalciferol | 9 | 2024 | 550 | 0.940 |
Why?
|
Hyperlipidemias | 3 | 2021 | 782 | 0.920 |
Why?
|
Insulin Resistance | 11 | 2024 | 3959 | 0.900 |
Why?
|
Middle Aged | 118 | 2024 | 220352 | 0.850 |
Why?
|
Dietary Supplements | 20 | 2024 | 3392 | 0.840 |
Why?
|
Female | 149 | 2024 | 391270 | 0.810 |
Why?
|
Humans | 217 | 2024 | 760621 | 0.810 |
Why?
|
Particle Size | 11 | 2023 | 1644 | 0.810 |
Why?
|
Apolipoproteins | 6 | 2022 | 320 | 0.790 |
Why?
|
Food Labeling | 1 | 2024 | 180 | 0.770 |
Why?
|
Proportional Hazards Models | 21 | 2024 | 12531 | 0.740 |
Why?
|
Fishes | 2 | 2024 | 601 | 0.730 |
Why?
|
Ventricular Premature Complexes | 1 | 2021 | 113 | 0.720 |
Why?
|
Glycosylation | 9 | 2024 | 1096 | 0.700 |
Why?
|
Aged | 84 | 2024 | 169152 | 0.680 |
Why?
|
Group II Phospholipases A2 | 1 | 2019 | 12 | 0.680 |
Why?
|
Vitamin D | 14 | 2024 | 3291 | 0.660 |
Why?
|
Incidence | 27 | 2022 | 21392 | 0.650 |
Why?
|
Anticholesteremic Agents | 4 | 2016 | 987 | 0.640 |
Why?
|
Coronary Artery Disease | 8 | 2022 | 6659 | 0.630 |
Why?
|
Glycoproteins | 2 | 2016 | 2208 | 0.630 |
Why?
|
Blood Chemical Analysis | 5 | 2019 | 437 | 0.620 |
Why?
|
Carbohydrates | 1 | 2020 | 388 | 0.610 |
Why?
|
Tunica Intima | 3 | 2012 | 459 | 0.610 |
Why?
|
Kringles | 1 | 2017 | 8 | 0.610 |
Why?
|
Spouses | 1 | 2020 | 279 | 0.610 |
Why?
|
Apolipoprotein B-100 | 3 | 2020 | 155 | 0.580 |
Why?
|
Inflammation Mediators | 3 | 2018 | 1881 | 0.580 |
Why?
|
Acute Coronary Syndrome | 4 | 2020 | 2365 | 0.580 |
Why?
|
Follow-Up Studies | 33 | 2022 | 39261 | 0.580 |
Why?
|
Double-Blind Method | 24 | 2024 | 12427 | 0.570 |
Why?
|
Calcinosis | 2 | 2022 | 1476 | 0.560 |
Why?
|
Body Mass Index | 19 | 2022 | 12914 | 0.540 |
Why?
|
Acetylgalactosamine | 1 | 2016 | 38 | 0.540 |
Why?
|
Prospective Studies | 36 | 2024 | 54303 | 0.530 |
Why?
|
Male | 98 | 2024 | 359744 | 0.520 |
Why?
|
Diagnostic Tests, Routine | 1 | 2021 | 786 | 0.490 |
Why?
|
Light | 1 | 2021 | 1344 | 0.490 |
Why?
|
Tunica Media | 2 | 2012 | 112 | 0.470 |
Why?
|
Obesity | 14 | 2023 | 12922 | 0.460 |
Why?
|
Deoxyglucose | 1 | 2014 | 333 | 0.450 |
Why?
|
Docosahexaenoic Acids | 5 | 2024 | 912 | 0.450 |
Why?
|
Biological Specimen Banks | 1 | 2019 | 783 | 0.450 |
Why?
|
Proteins | 4 | 2020 | 6029 | 0.450 |
Why?
|
Heptanoic Acids | 2 | 2014 | 347 | 0.450 |
Why?
|
Myocardial Ischemia | 2 | 2018 | 2164 | 0.440 |
Why?
|
Heart Rate | 4 | 2021 | 4179 | 0.440 |
Why?
|
Carotid Artery Diseases | 2 | 2012 | 883 | 0.440 |
Why?
|
Myocardial Infarction | 9 | 2023 | 11891 | 0.420 |
Why?
|
Prognosis | 23 | 2024 | 29658 | 0.410 |
Why?
|
Predictive Value of Tests | 14 | 2024 | 15289 | 0.410 |
Why?
|
Stroke | 12 | 2023 | 9962 | 0.400 |
Why?
|
Fibrinogen | 3 | 2018 | 886 | 0.380 |
Why?
|
Cacao | 2 | 2022 | 98 | 0.380 |
Why?
|
Risk | 10 | 2019 | 9631 | 0.360 |
Why?
|
Cause of Death | 5 | 2024 | 3725 | 0.360 |
Why?
|
Vitamins | 8 | 2023 | 1634 | 0.360 |
Why?
|
Postmenopause | 2 | 2021 | 2509 | 0.350 |
Why?
|
Mortality | 3 | 2024 | 2916 | 0.350 |
Why?
|
Polymorphism, Single Nucleotide | 13 | 2021 | 15789 | 0.350 |
Why?
|
Thyroid Gland | 3 | 2024 | 1168 | 0.350 |
Why?
|
Practice Guidelines as Topic | 5 | 2017 | 7475 | 0.340 |
Why?
|
Pyrroles | 2 | 2014 | 1137 | 0.330 |
Why?
|
Randomized Controlled Trials as Topic | 12 | 2018 | 10344 | 0.320 |
Why?
|
Cell Fractionation | 1 | 2009 | 251 | 0.320 |
Why?
|
Nuclear Magnetic Resonance, Biomolecular | 5 | 2018 | 511 | 0.320 |
Why?
|
Hemorrhage | 2 | 2018 | 3600 | 0.310 |
Why?
|
Clinical Laboratory Techniques | 2 | 2016 | 749 | 0.310 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2023 | 3455 | 0.310 |
Why?
|
Diet | 4 | 2024 | 8010 | 0.310 |
Why?
|
Aortic Valve Stenosis | 4 | 2023 | 2065 | 0.310 |
Why?
|
Intercellular Adhesion Molecule-1 | 3 | 2020 | 1126 | 0.300 |
Why?
|
Preventive Medicine | 1 | 2010 | 250 | 0.300 |
Why?
|
Sex Characteristics | 2 | 2021 | 2629 | 0.300 |
Why?
|
Cohort Studies | 18 | 2024 | 41335 | 0.300 |
Why?
|
Atrioventricular Block | 1 | 2009 | 121 | 0.300 |
Why?
|
Hypertension | 7 | 2021 | 8594 | 0.300 |
Why?
|
Eicosapentaenoic Acid | 5 | 2024 | 613 | 0.300 |
Why?
|
Pulmonary Valve Insufficiency | 1 | 2009 | 143 | 0.290 |
Why?
|
Hypothyroidism | 3 | 2021 | 665 | 0.280 |
Why?
|
Survival Rate | 5 | 2021 | 12808 | 0.280 |
Why?
|
Hypercholesterolemia | 4 | 2018 | 1155 | 0.280 |
Why?
|
Motor Activity | 4 | 2011 | 2687 | 0.270 |
Why?
|
Risk Reduction Behavior | 4 | 2016 | 1109 | 0.270 |
Why?
|
Time Factors | 13 | 2024 | 40165 | 0.270 |
Why?
|
Chest Pain | 1 | 2013 | 1106 | 0.270 |
Why?
|
Fibrinolytic Agents | 1 | 2016 | 2167 | 0.270 |
Why?
|
Guidelines as Topic | 2 | 2010 | 1392 | 0.270 |
Why?
|
Neoplasms | 12 | 2022 | 22072 | 0.260 |
Why?
|
Eating | 1 | 2012 | 1539 | 0.260 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 8056 | 0.260 |
Why?
|
Atrial Fibrillation | 4 | 2021 | 5209 | 0.260 |
Why?
|
Hyperglycemia | 1 | 2014 | 1380 | 0.260 |
Why?
|
Decision Making | 2 | 2016 | 3925 | 0.260 |
Why?
|
Age Factors | 7 | 2021 | 18416 | 0.250 |
Why?
|
Benchmarking | 3 | 2024 | 1044 | 0.250 |
Why?
|
United States | 19 | 2024 | 72461 | 0.250 |
Why?
|
Life Style | 3 | 2022 | 3896 | 0.250 |
Why?
|
Diabetic Retinopathy | 1 | 2014 | 1268 | 0.250 |
Why?
|
Cross-Sectional Studies | 14 | 2023 | 25942 | 0.240 |
Why?
|
Hypolipidemic Agents | 2 | 2020 | 626 | 0.240 |
Why?
|
Thyroxine | 3 | 2024 | 667 | 0.240 |
Why?
|
Cholesterol, VLDL | 2 | 2017 | 71 | 0.240 |
Why?
|
Sex Factors | 7 | 2020 | 10547 | 0.230 |
Why?
|
Case-Control Studies | 7 | 2024 | 22053 | 0.230 |
Why?
|
Carotid Arteries | 2 | 2011 | 951 | 0.220 |
Why?
|
Nutrition Surveys | 3 | 2016 | 1725 | 0.220 |
Why?
|
Program Evaluation | 1 | 2012 | 2493 | 0.220 |
Why?
|
Molecular Weight | 2 | 2020 | 2186 | 0.220 |
Why?
|
Consensus | 8 | 2022 | 3113 | 0.220 |
Why?
|
Glomerular Filtration Rate | 3 | 2022 | 2180 | 0.220 |
Why?
|
Colorectal Neoplasms | 4 | 2016 | 6853 | 0.210 |
Why?
|
Blood Pressure | 5 | 2018 | 8525 | 0.210 |
Why?
|
Placebos | 2 | 2020 | 1668 | 0.210 |
Why?
|
Leucine | 2 | 2021 | 547 | 0.200 |
Why?
|
Adult | 32 | 2024 | 219994 | 0.200 |
Why?
|
Metabolomics | 2 | 2024 | 1628 | 0.200 |
Why?
|
Hyperthyroidism | 2 | 2021 | 291 | 0.200 |
Why?
|
Vitamin E | 3 | 2018 | 872 | 0.200 |
Why?
|
Diabetes Mellitus | 4 | 2019 | 5889 | 0.200 |
Why?
|
Communications Media | 1 | 2022 | 42 | 0.190 |
Why?
|
Health Promotion | 2 | 2022 | 2206 | 0.190 |
Why?
|
Adiposity | 3 | 2021 | 1858 | 0.190 |
Why?
|
Models, Theoretical | 1 | 2013 | 3562 | 0.180 |
Why?
|
Disease Progression | 2 | 2019 | 13502 | 0.180 |
Why?
|
Seafood | 1 | 2024 | 390 | 0.180 |
Why?
|
Immunoglobulin G | 3 | 2024 | 4541 | 0.180 |
Why?
|
Breast Neoplasms | 5 | 2022 | 21025 | 0.180 |
Why?
|
Reference Values | 3 | 2020 | 4925 | 0.180 |
Why?
|
Kaplan-Meier Estimate | 4 | 2017 | 6544 | 0.180 |
Why?
|
Treatment Outcome | 13 | 2024 | 65017 | 0.170 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2014 | 2290 | 0.170 |
Why?
|
Anti-Inflammatory Agents | 2 | 2020 | 1796 | 0.170 |
Why?
|
Genome-Wide Association Study | 9 | 2024 | 12626 | 0.170 |
Why?
|
Fish Oils | 2 | 2023 | 482 | 0.170 |
Why?
|
Mendelian Randomization Analysis | 3 | 2021 | 998 | 0.170 |
Why?
|
Secondary Prevention | 3 | 2019 | 1548 | 0.170 |
Why?
|
Patient Education as Topic | 1 | 2010 | 2315 | 0.170 |
Why?
|
Apolipoprotein E4 | 1 | 2024 | 707 | 0.170 |
Why?
|
Angina, Unstable | 3 | 2013 | 926 | 0.170 |
Why?
|
Chemistry, Clinical | 2 | 2016 | 64 | 0.160 |
Why?
|
Societies, Medical | 4 | 2020 | 3905 | 0.160 |
Why?
|
Diet, Carbohydrate-Restricted | 1 | 2022 | 261 | 0.160 |
Why?
|
Patient Compliance | 2 | 2024 | 2688 | 0.160 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 317 | 0.160 |
Why?
|
Morbidity | 2 | 2017 | 1765 | 0.160 |
Why?
|
Oxylipins | 1 | 2019 | 52 | 0.160 |
Why?
|
Hemostasis | 1 | 2021 | 468 | 0.160 |
Why?
|
Heart Failure | 5 | 2024 | 11847 | 0.160 |
Why?
|
Peripheral Arterial Disease | 3 | 2019 | 1306 | 0.160 |
Why?
|
Multivariate Analysis | 5 | 2017 | 12159 | 0.150 |
Why?
|
Diet, Reducing | 1 | 2022 | 488 | 0.150 |
Why?
|
Apolipoprotein C-III | 1 | 2019 | 209 | 0.150 |
Why?
|
Fatty Acids, Omega-6 | 1 | 2019 | 227 | 0.150 |
Why?
|
Vitamin D Deficiency | 3 | 2024 | 1379 | 0.150 |
Why?
|
Fatty Acids | 3 | 2023 | 1804 | 0.150 |
Why?
|
Cardiology | 3 | 2019 | 1723 | 0.150 |
Why?
|
Databases, Protein | 1 | 2020 | 388 | 0.150 |
Why?
|
North America | 1 | 2021 | 1284 | 0.150 |
Why?
|
Asthma | 1 | 2017 | 6172 | 0.150 |
Why?
|
Overweight | 3 | 2023 | 2421 | 0.150 |
Why?
|
Confidence Intervals | 2 | 2014 | 2932 | 0.150 |
Why?
|
Specimen Handling | 1 | 2022 | 707 | 0.140 |
Why?
|
Up-Regulation | 4 | 2019 | 4122 | 0.140 |
Why?
|
Plasma | 1 | 2020 | 584 | 0.140 |
Why?
|
Immunoassay | 2 | 2014 | 746 | 0.140 |
Why?
|
Thyroid Hormones | 1 | 2020 | 403 | 0.140 |
Why?
|
Heart Valves | 1 | 2019 | 285 | 0.140 |
Why?
|
Eicosanoids | 1 | 2019 | 278 | 0.140 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2010 | 3986 | 0.140 |
Why?
|
Age of Onset | 2 | 2021 | 3301 | 0.140 |
Why?
|
Respiratory Tract Infections | 1 | 2024 | 1007 | 0.130 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2017 | 186 | 0.130 |
Why?
|
Caloric Restriction | 1 | 2018 | 296 | 0.130 |
Why?
|
Thyroid Diseases | 1 | 2019 | 386 | 0.130 |
Why?
|
Severity of Illness Index | 5 | 2021 | 15840 | 0.130 |
Why?
|
Preventive Health Services | 1 | 2000 | 570 | 0.130 |
Why?
|
Prevalence | 6 | 2020 | 15687 | 0.130 |
Why?
|
Europe | 3 | 2016 | 3441 | 0.120 |
Why?
|
Lipid Metabolism | 2 | 2021 | 1902 | 0.120 |
Why?
|
Peptic Ulcer | 1 | 2016 | 219 | 0.120 |
Why?
|
Smoking | 4 | 2021 | 9073 | 0.120 |
Why?
|
Diabetic Nephropathies | 1 | 2022 | 988 | 0.120 |
Why?
|
Ion Transport | 1 | 2015 | 318 | 0.120 |
Why?
|
Algorithms | 4 | 2021 | 13981 | 0.120 |
Why?
|
Genetic Predisposition to Disease | 8 | 2021 | 17790 | 0.110 |
Why?
|
Myocardial Revascularization | 2 | 2020 | 841 | 0.110 |
Why?
|
Chemoprevention | 1 | 2016 | 326 | 0.110 |
Why?
|
ROC Curve | 2 | 2015 | 3568 | 0.110 |
Why?
|
Blood Vessels | 1 | 2019 | 1112 | 0.110 |
Why?
|
Thyrotropin | 3 | 2024 | 832 | 0.110 |
Why?
|
Physical Endurance | 2 | 2006 | 363 | 0.110 |
Why?
|
Longitudinal Studies | 3 | 2020 | 14495 | 0.110 |
Why?
|
Cardiovascular System | 1 | 2021 | 850 | 0.110 |
Why?
|
Health Status Indicators | 1 | 2018 | 968 | 0.110 |
Why?
|
Homocysteine | 2 | 2007 | 640 | 0.110 |
Why?
|
Ligands | 1 | 2020 | 3276 | 0.110 |
Why?
|
Hematuria | 1 | 2014 | 233 | 0.110 |
Why?
|
Aged, 80 and over | 14 | 2021 | 58995 | 0.110 |
Why?
|
Fibroblast Growth Factors | 1 | 2018 | 869 | 0.100 |
Why?
|
Genotype | 7 | 2024 | 12960 | 0.100 |
Why?
|
Aorta, Thoracic | 1 | 2019 | 1097 | 0.100 |
Why?
|
Ultrasonography | 3 | 2012 | 5961 | 0.100 |
Why?
|
Calcium | 2 | 2023 | 5725 | 0.100 |
Why?
|
Patient Admission | 1 | 2019 | 1386 | 0.100 |
Why?
|
Body Composition | 1 | 2021 | 2419 | 0.100 |
Why?
|
Carotid Artery, Common | 1 | 2012 | 177 | 0.100 |
Why?
|
New England | 2 | 2024 | 1050 | 0.090 |
Why?
|
Reproducibility of Results | 6 | 2022 | 20080 | 0.090 |
Why?
|
Blood Proteins | 1 | 2016 | 1173 | 0.090 |
Why?
|
Endpoint Determination | 1 | 2013 | 597 | 0.090 |
Why?
|
Research | 1 | 2019 | 1974 | 0.090 |
Why?
|
Lipoproteins, IDL | 1 | 2010 | 18 | 0.090 |
Why?
|
Asymptomatic Diseases | 1 | 2013 | 587 | 0.090 |
Why?
|
Electronic Health Records | 2 | 2024 | 4775 | 0.090 |
Why?
|
Down-Regulation | 1 | 2017 | 2913 | 0.090 |
Why?
|
Early Termination of Clinical Trials | 1 | 2010 | 71 | 0.090 |
Why?
|
Triiodothyronine | 2 | 2024 | 493 | 0.090 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 3618 | 0.090 |
Why?
|
Creatinine | 3 | 2020 | 1903 | 0.080 |
Why?
|
Carotid Artery, Internal | 1 | 2012 | 438 | 0.080 |
Why?
|
Single-Blind Method | 1 | 2013 | 1578 | 0.080 |
Why?
|
Odds Ratio | 3 | 2014 | 9716 | 0.080 |
Why?
|
Heart | 1 | 2022 | 4393 | 0.080 |
Why?
|
Middle East | 2 | 2020 | 230 | 0.080 |
Why?
|
Treatment Failure | 3 | 2021 | 2648 | 0.080 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2016 | 1131 | 0.080 |
Why?
|
Kidney Diseases | 1 | 2020 | 2093 | 0.080 |
Why?
|
Migraine Disorders | 1 | 2021 | 1693 | 0.080 |
Why?
|
Thyroid Function Tests | 2 | 2020 | 289 | 0.080 |
Why?
|
Age Distribution | 1 | 2014 | 2893 | 0.080 |
Why?
|
Proteomics | 1 | 2022 | 3817 | 0.080 |
Why?
|
Diabetes, Gestational | 1 | 2018 | 1242 | 0.080 |
Why?
|
Comorbidity | 4 | 2020 | 10551 | 0.080 |
Why?
|
Psoriasis | 1 | 2016 | 940 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2021 | 10827 | 0.070 |
Why?
|
Feeding Behavior | 1 | 2020 | 3185 | 0.070 |
Why?
|
Angioplasty | 1 | 2010 | 361 | 0.070 |
Why?
|
Arthritis, Rheumatoid | 1 | 2023 | 3763 | 0.070 |
Why?
|
Genome, Human | 2 | 2017 | 4417 | 0.070 |
Why?
|
American Heart Association | 1 | 2012 | 1081 | 0.070 |
Why?
|
Physician-Patient Relations | 1 | 2000 | 3242 | 0.070 |
Why?
|
Hospitalization | 3 | 2022 | 10790 | 0.070 |
Why?
|
Drug Administration Schedule | 2 | 2012 | 4899 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2020 | 5425 | 0.070 |
Why?
|
Health Behavior | 1 | 2018 | 2622 | 0.070 |
Why?
|
Calibration | 1 | 2009 | 816 | 0.070 |
Why?
|
Terminology as Topic | 1 | 2013 | 1535 | 0.070 |
Why?
|
Communication | 1 | 2000 | 3849 | 0.070 |
Why?
|
Software | 1 | 2020 | 4419 | 0.070 |
Why?
|
Parathyroid Hormone | 2 | 2023 | 1797 | 0.070 |
Why?
|
Liver Diseases | 1 | 2014 | 1302 | 0.060 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2007 | 275 | 0.060 |
Why?
|
Muscular Diseases | 1 | 2010 | 551 | 0.060 |
Why?
|
Health Status | 1 | 2018 | 4081 | 0.060 |
Why?
|
Depressive Disorder, Major | 1 | 2023 | 4744 | 0.060 |
Why?
|
Waist Circumference | 2 | 2020 | 926 | 0.060 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2014 | 1079 | 0.060 |
Why?
|
Vitamin B Complex | 1 | 2007 | 297 | 0.060 |
Why?
|
Massachusetts | 1 | 2017 | 8803 | 0.060 |
Why?
|
Primary Health Care | 1 | 2021 | 4647 | 0.060 |
Why?
|
Kidney | 1 | 2020 | 7064 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2016 | 3696 | 0.060 |
Why?
|
Disease-Free Survival | 1 | 2014 | 6828 | 0.060 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2012 | 1004 | 0.060 |
Why?
|
Biomedical Research | 1 | 2019 | 3426 | 0.060 |
Why?
|
Canada | 2 | 2022 | 2128 | 0.060 |
Why?
|
Death, Sudden, Cardiac | 1 | 2012 | 1572 | 0.060 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2852 | 0.050 |
Why?
|
Air Pollutants | 1 | 2017 | 2844 | 0.050 |
Why?
|
Chronic Disease | 1 | 2018 | 9287 | 0.050 |
Why?
|
Inheritance Patterns | 1 | 2005 | 340 | 0.050 |
Why?
|
Child | 3 | 2021 | 79806 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2020 | 5351 | 0.050 |
Why?
|
Data Collection | 1 | 2012 | 3315 | 0.050 |
Why?
|
Patient Selection | 1 | 2014 | 4283 | 0.050 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2006 | 377 | 0.050 |
Why?
|
Thrombosis | 2 | 2006 | 3052 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2017 | 4412 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2008 | 14660 | 0.050 |
Why?
|
Heart Arrest | 1 | 2012 | 1506 | 0.050 |
Why?
|
Isoleucine | 1 | 2021 | 110 | 0.050 |
Why?
|
Diabetes Complications | 1 | 2008 | 1341 | 0.050 |
Why?
|
Adolescent | 4 | 2022 | 87810 | 0.050 |
Why?
|
Trace Elements | 1 | 2023 | 196 | 0.050 |
Why?
|
Boston | 1 | 2014 | 9280 | 0.050 |
Why?
|
Epidemiologic Methods | 2 | 2021 | 1343 | 0.050 |
Why?
|
Siblings | 1 | 2005 | 824 | 0.050 |
Why?
|
Intention to Treat Analysis | 1 | 2022 | 422 | 0.050 |
Why?
|
Blood Coagulation Tests | 1 | 2021 | 270 | 0.040 |
Why?
|
Prediabetic State | 1 | 2006 | 550 | 0.040 |
Why?
|
Genetic Loci | 1 | 2009 | 2618 | 0.040 |
Why?
|
Cation Transport Proteins | 1 | 2023 | 325 | 0.040 |
Why?
|
Folic Acid | 1 | 2007 | 1309 | 0.040 |
Why?
|
Family Health | 1 | 2005 | 1257 | 0.040 |
Why?
|
Fibrinolysis | 1 | 2021 | 332 | 0.040 |
Why?
|
Metabolic Networks and Pathways | 1 | 2024 | 789 | 0.040 |
Why?
|
Internet | 1 | 2012 | 3078 | 0.040 |
Why?
|
Africa, Northern | 1 | 2019 | 86 | 0.040 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2023 | 599 | 0.040 |
Why?
|
Nomograms | 1 | 2021 | 238 | 0.040 |
Why?
|
Blood Coagulation Factors | 1 | 2021 | 365 | 0.040 |
Why?
|
Endothelium, Vascular | 1 | 2011 | 4433 | 0.040 |
Why?
|
Epidemiologic Studies | 1 | 2022 | 670 | 0.040 |
Why?
|
Plant Extracts | 1 | 2022 | 496 | 0.040 |
Why?
|
Blood Glucose | 2 | 2018 | 6381 | 0.040 |
Why?
|
DNA | 2 | 2010 | 7233 | 0.040 |
Why?
|
Apolipoproteins E | 1 | 2024 | 1436 | 0.040 |
Why?
|
Femur Neck | 1 | 2020 | 312 | 0.040 |
Why?
|
Autocrine Communication | 1 | 1999 | 169 | 0.040 |
Why?
|
Myometrium | 1 | 1999 | 176 | 0.040 |
Why?
|
Muscles | 1 | 2023 | 1581 | 0.040 |
Why?
|
Linear Models | 2 | 2019 | 5877 | 0.040 |
Why?
|
Young Adult | 4 | 2022 | 58741 | 0.040 |
Why?
|
Kidney Function Tests | 1 | 2020 | 681 | 0.040 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2019 | 346 | 0.040 |
Why?
|
Poisson Distribution | 1 | 2019 | 507 | 0.040 |
Why?
|
Phenotype | 3 | 2021 | 16546 | 0.040 |
Why?
|
Regression Analysis | 1 | 2007 | 6360 | 0.040 |
Why?
|
von Willebrand Factor | 1 | 2021 | 673 | 0.040 |
Why?
|
Bone Density | 2 | 2021 | 3534 | 0.040 |
Why?
|
Metabolome | 1 | 2024 | 982 | 0.040 |
Why?
|
Iodide Peroxidase | 1 | 2019 | 294 | 0.040 |
Why?
|
Paracrine Communication | 1 | 1999 | 277 | 0.040 |
Why?
|
Premenopause | 1 | 2021 | 1038 | 0.040 |
Why?
|
Prolactin | 1 | 1999 | 621 | 0.030 |
Why?
|
Attitude | 1 | 2022 | 777 | 0.030 |
Why?
|
Growth Substances | 1 | 1999 | 768 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2021 | 1376 | 0.030 |
Why?
|
Animals | 4 | 2024 | 167963 | 0.030 |
Why?
|
Socioeconomic Factors | 2 | 2020 | 7806 | 0.030 |
Why?
|
England | 1 | 2017 | 526 | 0.030 |
Why?
|
Glycomics | 1 | 2017 | 109 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2008 | 5508 | 0.030 |
Why?
|
Blood Coagulation | 1 | 2021 | 1157 | 0.030 |
Why?
|
Netherlands | 1 | 2020 | 2213 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2019 | 1544 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2019 | 805 | 0.030 |
Why?
|
Water | 1 | 2021 | 1407 | 0.030 |
Why?
|
Body Weight | 1 | 2005 | 4611 | 0.030 |
Why?
|
Decision Support Techniques | 1 | 2024 | 2001 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2009 | 12965 | 0.030 |
Why?
|
Leiomyoma | 1 | 1999 | 654 | 0.030 |
Why?
|
Absorptiometry, Photon | 1 | 2020 | 1736 | 0.030 |
Why?
|
Seasons | 1 | 2019 | 1522 | 0.030 |
Why?
|
Minority Groups | 1 | 2020 | 1201 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2000 | 2659 | 0.030 |
Why?
|
Pulse | 1 | 2013 | 218 | 0.030 |
Why?
|
Erythrocytes | 1 | 2022 | 2415 | 0.030 |
Why?
|
Survival Analysis | 1 | 2005 | 10182 | 0.030 |
Why?
|
Autoantibodies | 1 | 2021 | 2118 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2019 | 1189 | 0.030 |
Why?
|
HIV Infections | 1 | 2019 | 17165 | 0.030 |
Why?
|
Electrocardiography | 1 | 2005 | 6414 | 0.020 |
Why?
|
Nurses | 1 | 2021 | 2467 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2024 | 7021 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6498 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2018 | 1974 | 0.020 |
Why?
|
Quality of Life | 1 | 2012 | 13308 | 0.020 |
Why?
|
Weight Loss | 1 | 2022 | 2686 | 0.020 |
Why?
|
Uterine Neoplasms | 1 | 1999 | 1439 | 0.020 |
Why?
|
Viral Load | 1 | 2019 | 3322 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2019 | 2062 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2019 | 3215 | 0.020 |
Why?
|
Genetic Markers | 1 | 2015 | 2608 | 0.020 |
Why?
|
Biological Transport | 1 | 2013 | 2086 | 0.020 |
Why?
|
Computational Biology | 1 | 2021 | 3505 | 0.020 |
Why?
|
Plaque, Atherosclerotic | 1 | 2019 | 1518 | 0.020 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2013 | 571 | 0.020 |
Why?
|
Aging | 1 | 2006 | 8651 | 0.020 |
Why?
|
Insulin | 1 | 2022 | 6597 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2016 | 80372 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2015 | 2326 | 0.020 |
Why?
|
Smoking Cessation | 1 | 2018 | 2064 | 0.020 |
Why?
|
Cognition | 1 | 2024 | 6957 | 0.020 |
Why?
|
Models, Statistical | 1 | 2021 | 5075 | 0.020 |
Why?
|
Administration, Oral | 1 | 2014 | 4035 | 0.020 |
Why?
|
Logistic Models | 1 | 2000 | 13314 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 3323 | 0.020 |
Why?
|
Patient Participation | 1 | 2014 | 1439 | 0.020 |
Why?
|
Quality of Health Care | 2 | 2009 | 4360 | 0.010 |
Why?
|
Medicare | 1 | 2022 | 6786 | 0.010 |
Why?
|
Gene Frequency | 1 | 2010 | 3615 | 0.010 |
Why?
|
Depression | 1 | 2023 | 8044 | 0.010 |
Why?
|
Research Design | 1 | 2019 | 6180 | 0.010 |
Why?
|
Hemodynamics | 1 | 2013 | 4174 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2011 | 3301 | 0.010 |
Why?
|
Models, Genetic | 1 | 2009 | 3442 | 0.010 |
Why?
|
Alleles | 1 | 2010 | 6898 | 0.010 |
Why?
|
Receptors, Prolactin | 1 | 1999 | 16 | 0.010 |
Why?
|
Blotting, Southern | 1 | 1999 | 777 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2007 | 6068 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 2696 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2007 | 4291 | 0.010 |
Why?
|
Pregnancy | 1 | 2018 | 29749 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1999 | 1705 | 0.010 |
Why?
|
Cell Count | 1 | 1999 | 1835 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2017 | 13630 | 0.010 |
Why?
|
Mitosis | 1 | 1999 | 1191 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13262 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 4573 | 0.010 |
Why?
|
Cell Division | 1 | 1999 | 4463 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1999 | 6131 | 0.010 |
Why?
|
Antibodies | 1 | 1999 | 2421 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1999 | 12766 | 0.000 |
Why?
|